39 Personalized Medicine in Cancer Treatment Flashcards
(117 cards)
What is pharmacogenetics?
The study of the genetic determinants of drug response variability
Germline or constitutional variants can impact disease treatments
What can polymorphic variant alleles do to the drug metabolism?
- activate a prodrug to its active form
- catalyze the inactivation and elimination of a drug or metabolite
What is the most important enzyme complex in drug metabolism?
cytochrome P450 superfamily (CYP)
It directly affect the pharmacokinetics of many drugs.
What is Cytochrome P450?
Cytochrome P450 is a hemeprotein
Plays a key role in the metabolism of drugs and other xenobiotics
It directly affect the pharmacokinetics of many drugs.
Besides CYP450 and enzymes, what other proteins are important for drug metabolism?
Cell receptors –> play a role in pharmacodynamics
Genetic variants in cell receptors can influence drug transport
What are the phases of drug metabolism?
phase I reactions
phase II reactions
What is the phase I of drug metabolism?
introduce reactive or polar groups
(-OH, -COOH, -NH2, -SH, etc.) into drugs, including oxidation, reduction, and hydrolysis,
where drugs cannot be excreted from bodies.
What is the phase II of drug metabolism?
The phase I modified drugs are conjugated to polar compounds by a variety of transferase enzymes, such as
uridine diphosphate (UDP)-glucuronosyltransferases,
sulfotransferases,
glutathione S-transferases
General pathways of drug metabolism
Phase I reactions –> Phase II reactions –> The conjugated drugs may be further processed, before being recognized by efflux transporters and pumped out of cells.
See the figure.
Contribution of different enzymes to drug metabolism:
CYP450
UGT, UDG glucuronosyl transferase;
FMO, flavin-containing monooxygenase;
NAT, N-acetyltransferase;
MAO, monoamine oxidase.
see the figure:
73% by CYP450
15% by UGT
What drugs are Fluoropyrimidines?
Fluoropyrimidines are a class of anti-cancer drugs, or more specifically antimetabolites.
Examples:
Capecitabine
Fluorouracil (5-FU)
Tegafur (Ftorafur®)
What type of cancers are treated by Fluoropyrimidines?
Solid tumors, such as breast and colorectal cancers.
What is an antineoplastic agent?
An antineoplastic agent is a chemotherapeutic agent that controls or kills cancer cells.
1) They are cytotoxic (inhibit or prevent cell function)
2) They are generally more damaging to dividing cells than resting cells.
3) Antineoplastic drugs are a subset of hazardous drugs.
What are the inactive prodrugs of 5-FU?
Capecitabine
Tegafur
What is the main mechanism of 5-FU activation?
Conversion from 5-FU to fluorodeoxyuridine monophosphate –>
inhibits thymidylate synthase
What is thymidylate synthase?
an important part of the folate-homocysteine cycle
and
purine and pyrimidine synthesis
What is the effect of 5-FU?
increased base excision repair damage–>DNA fragmentation and cell death.
the fluorouridine triphosphate metabolite can be incorporated into RNA in place of uridine triphosphate –> interfering with RNA processing and protein synthesis
What is the rate-limiting step of 5-FU catabolism?
Dihydropyrimindine dehydrogenase (DPD) conversion of 5-FU to dihydrofluorouracil
DPYD gene
1) Gene name for dihydropyrimidine dehydrogenase (DPD)
2) located at chr. 1p21.3
DPYD gene mutations
1) decrease DPD activity
2) increase drug half-life
3) severe or fatal 5-FU toxicity
What are the recommendations made by Clinical Pharmacogenetics Implementation Consortium (CPIC) for the DPYD gene mutations and 5-FU dosing?
1) 50% reduction in starting dose for patients who are heterozygous for a nonfunctional DPYD variant
2) an alternate therapy for patients with two nonfunctional DPYD variants (homozygous or compound heterozygous)
DPD deficiency
– homozygous loss-of-function
– an autosomal recessive disorder
– can be symptomatic and asymptomatic
– characterized by a wide range of severity : can have severe convulsive disorders with motor and mental retardation
– >50 mutations identified for DPD deficiency
– 3-5% Caucasian population has partial DPD deficiency
DPYD*2A
The mutation IVS14 + 1 G > A, DPYD*2A, is the most common mutation associated with DPD deficiency.
A G > A base change at the splice recognition sequence of intron 14, leads to exon skipping and results in a 165-bp deletion in the DPD mRNA
DPYD mutations detection
– Specimen: whole blood or tissues
– genotyping target: DPYD*2A decreased activity allele
– sequencing